![]() ![]() Invicro’s team of scientific experts provide a consultative approach to study design, execution, analysis, and reporting. Multiplex Immunofluorescence is an effective approach to examine the colocalization of infiltrating immune cells within the tissue microenvironment, which is particularly important in immuno-oncology drug development.ĭeveloping multiplex immunofluorescent assays and analyzing the data is a challenging process that requires domain knowledge and expertise. Immunofluorescence (IF) is a powerful approach to detect and visualize multiple (e.g., 4-plex, 8-plex) biomarkers while preserving tissue morphology to understand spatial relationships. Multiplex IHC combined with RNAScope® ISHĭOWNLOAD IHC BIOMARKER LIST Multiplex Immunostain Examples.Our laboratories are equipped with the latest research and clinical tissue processing equipment from Leica, Agilent Dako, Biocare Medical and Ventana to support your specific project needs. With multiple laboratory locations and CAP-accredited CLIA-certified sites, we offer comprehensive IHC services to support projects with varying levels of complexity. It is our mission to provide biomarker insights needed to help you make smart decisions that will accelerate drug development efforts. We perform IHC on xenograft tumor models, tissue microarrays (TMA), and a diverse population of human and non-human tissue samples. From early-stage discovery to exploratory endpoint testing and CDx development, our team is prepared to support all your project needs to expedite drug discovery and development efforts. Our laboratories possess the scientific, regulatory and operational expertise to develop and run immunohistochemistry (IHC) assays across multiple therapeutic areas. ![]() With rapid advancements made in the field of immunotherapy, IHC remains a valuable assay to support the development and approval of cutting-edge therapies. In clinical practice and drug development, IHC is widely used as a companion diagnostic test to stratify patients and monitor the efficacy of therapeutic treatments. IHC allows for the visualization of target antigens on the cellular and subcellular level with tissue morphology preserved in a wide-range of sample types, such as solid tumor biopsies, lymph nodes and other isolated tissues. Immunohistochemistry (IHC) is a powerful tissue-based method used both in research and clinical diagnostics to evaluate pathological conditions. Companion Diagnostic (CDx) development for IHC and RNAScope® ISHĭownload our translational tissue biomarker services flyer here!.510(k) tissue-based submission tests for medical devices.Non-GLP Tissue Cross-Reactivity (TCR) assays.Pathologist consultation and immunostaining interpretation.RNAScope®, BaseScope™ and miRNAScope™ ISH.Immunohistochemistry (IHC) / Immunofluorescence (IF).Assay design, development and validation.When partnering with Invicro, we ensure both sides are aligned on expectations and provide the highest level of transparency expected from a contract research partner. Our unparalleled scientific expertise coupled with our operational capabilities allows us to support a variety of project types.įor all projects processed in our laboratory, our dedicated scientific and project management teams collaborate closely with sponsors to design studies that will deliver the insights needed to support research efforts at all stages of discovery and development. We support studies across many therapeutic areas, including oncology, immuno-oncology, neurology, immunology and systemic diseases. Invicro’s Advanced Pathology Services multidisciplinary team provides end-to-end discovery, translational research and clinical trial pathology services for pharmaceutical and biotechnology partners. With laboratory locations in Boston, MA, Irvine, CA, and Japan, we are able to support projects spanning all phases of drug discovery and development. Our scientific, operational and regulatory expertise enables us to deliver insights needed to take lead drug candidates to the next level.Īs an early-phase and clinical service provider, we offer routine and novel pathology services, including core histology, specialty stains, multiplex Immunohistochemistry (IHC), multiplex immunofluorescence (IF), Advanced Cell Diagnostics (ACD) RNAScope®, BaseScope™ and miRNAScope™ ISH with the option to perform select assays in a CAP-accredited, CLIA-certified laboratory. ![]() group, our pathology service laboratories support projects spanning preclinical biomarker discovery research to clinical trials and development of companion diagnostics (CDx) products. Invicro’s Advanced Pathology Services (APS) team provides end-to-end solutions to support translational and clinical research by providing a combination of routine and unique tissue testing services. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |